Suppr超能文献

Immediate onset of sterile endophthalmitis with hypopyon after intravitreal Brolucizumab in a case of polypoidal choroidal vasculopathy.

作者信息

Narayanan Raja, Tyagi Mudit, Gupta Shashank R, Nayaka Ashraya, Jayadev Chaitra

机构信息

Smt. Kanuri Santhamma Vitreoretina Service, L.V. Prasad Eye Institute, Hyderabad, Telangana, India.

Delhi Eye Care, New Delhi, India.

出版信息

Indian J Ophthalmol. 2021 Feb;69(2):469-470. doi: 10.4103/ijo.IJO_3436_20.

Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c689/7933883/fa30cc46164a/IJO-69-469-g001.jpg

相似文献

4
Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for polypoidal choroidal vasculopathy.
Am J Ophthalmol. 2010 Jun;149(6):947-954.e1. doi: 10.1016/j.ajo.2009.12.038. Epub 2010 Mar 26.
6
Anti-vascular endothelial growth factor monotherapy in the treatment of submacular hemorrhage secondary to polypoidal choroidal vasculopathy.
Am J Ophthalmol. 2013 Sep;156(3):524-531.e1. doi: 10.1016/j.ajo.2013.04.029. Epub 2013 Jun 13.
7
Intravitreal bevacizumab for exudative branching vascular networks in polypoidal choroidal vasculopathy.
Br J Ophthalmol. 2012 Mar;96(3):394-9. doi: 10.1136/bjo.2011.204123. Epub 2011 Jun 30.
8
Relationship between clinical characteristics of polypoidal choroidal vasculopathy and choroidal vascular hyperpermeability.
Am J Ophthalmol. 2013 Feb;155(2):305-313.e1. doi: 10.1016/j.ajo.2012.07.018. Epub 2012 Sep 27.
10
Reduced-fluence photodynamic therapy combined with intravitreal bevacizumab for polypoidal choroidal vasculopathy.
Am J Ophthalmol. 2012 May;153(5):873-882.e2. doi: 10.1016/j.ajo.2011.09.031. Epub 2012 Jan 20.

引用本文的文献

3
Angiographic findings before and after the onset of brolucizumab-associated retinal vascular occlusion and intraocular inflammation.
Am J Ophthalmol Case Rep. 2022 Apr 14;26:101521. doi: 10.1016/j.ajoc.2022.101521. eCollection 2022 Jun.
4
Side Effects of Brolucizumab.
J Ophthalmic Vis Res. 2021 Oct 25;16(4):670-675. doi: 10.18502/jovr.v16i4.9757. eCollection 2021 Oct-Dec.
5
Current perspectives on use of anti-vascular endothelial growth factor agents for retinal disorders.
Indian J Ophthalmol. 2021 Feb;69(2):209-210. doi: 10.4103/ijo.IJO_72_21.

本文引用的文献

1
HAWK and HARRIER: Ninety-Six-Week Outcomes from the Phase 3 Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.
Ophthalmology. 2021 Jan;128(1):89-99. doi: 10.1016/j.ophtha.2020.06.028. Epub 2020 Jun 20.
2
Retinal Vasculitis and Intraocular Inflammation after Intravitreal Injection of Brolucizumab.
Ophthalmology. 2020 Oct;127(10):1345-1359. doi: 10.1016/j.ophtha.2020.04.017. Epub 2020 Apr 25.
3
The safety and side effects of monoclonal antibodies.
Nat Rev Drug Discov. 2010 Apr;9(4):325-38. doi: 10.1038/nrd3003. Epub 2010 Mar 22.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验